Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daridorexant QT Interval Study
NCT04250506Phase 1Completed
- Sponsor
- Idorsia
- Start
- Feb 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of daridorexant in Insomnia (4 arms), sponsored by Idorsia. Primary endpoint: Placebo-corrected change from baseline in the HR-corrected QTcF at Day 2. Started Feb 2020; status: completed.
02
Drugs
daridorexant
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT04250506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04250506.